ORTEXORTEX News
Tracking CF? Get live short interest, options flow, and signals on ORTEX.Sign up free →
CF
Trader NoteCF

CF Industries Shorts Rebuild as Earnings Loom

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 24 Oct 2026, 20:10

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Short sellers have been quietly rebuilding positions in CF Industries over the past month, even as the stock has held its ground better than most of its peers this week.

Short interest has climbed 17% over the past 30 days, reaching 6.4% of the free float. The pace of accumulation is the standout: from roughly 8.2 million shares short in late September to just under 10 million by October 22. That move has been steady rather than abrupt, suggesting a deliberate tilt rather than a momentum-driven pile-on. On the week, the position barely budged, up 0.5%, which means the rebuild largely happened in the first three weeks of October and has since plateaued.

The lending market tells a different story. Borrow costs have been falling, down 22% on the week to 0.42%, and availability is exceptionally loose at 1,250% of current short interest. There is no shortage of shares to borrow, and no squeeze pressure in the mechanics of the trade. Borrowing CF is cheap and easy right now, which is consistent with the size of the short rebuild but not with any urgency behind it. Options positioning also looks relaxed. The put/call ratio of 0.77 sits almost exactly at its 20-day average, with a z-score near zero. The options market shows no particular skew toward protection ahead of the November 4 earnings date.

Analysts have been more active than the stock's flat week might suggest. CIBC raised its target to $133 from $125 on October 23, maintaining a Neutral rating. Bernstein initiated coverage with an Outperform and a $162 target in late September, while Keybanc took the opposing view with an Underweight and a $115 target. The mean target across the Street is $128, roughly 6% above the current price of $120.68. The bull case rests on stabilising nitrogen valuations, growing demand for low-carbon ammonia, and cash flows that support buybacks through the Blue Point project buildout. Bears point to the risk of rising Chinese urea exports and seasonal demand softness in the second half of the year compressing pricing power. The earnings yield factor ranks in the 88th percentile and the EV/EBIT score in the 81st, suggesting the stock is not expensive on an earnings basis even after a 50% year-to-date run. Forward EPS momentum over 12 months ranks near the bottom of the universe at the 8th percentile, however, a reminder that the earnings growth case depends heavily on commodity prices holding up.

Among the closest peers, LXU fell nearly 7% on the week and NTR dropped 3.2%, while DOW bucked the trend with a near-9% weekly gain. CF's flat week, down just 0.1%, sits comfortably above the median for its peer group, which shed around 2.7% on average. Wikipedia attention for CF is running well above its own 90-day baseline, with a z-score of 2.0 as of October 22, the highest retail attention signal in the dataset for this stock in recent months.

The ORTEX short score of 44.97 has been essentially flat for the past 10 days, consistent with a position that has been reset rather than one that is actively building. What arrives on November 4 is a Q3 print that will test whether the short rebuild was prescient on pricing pressure or premature given the relative resilience of domestic nitrogen demand.

Stocks in this article

See the live data behind this article on ORTEX.

Open CF on ORTEX →

How this article was generated

Generated
24 Oct 2026, 20:11
Data as of
24 Oct 2026, 20:10
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.